MARKSANS PHARMA
Quarterly Results Analysis [Jun2026]
MARKSANS PHARMA Quarterly Results
| Consolidated | Jun2026 UnAudited |
Mar2026 UnAudited |
Dec2025 UnAudited |
Sep2025 UnAudited |
Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
|---|---|---|---|---|---|---|---|---|
| Revenues | ₹841 Cr | ₹856 Cr | ₹754 Cr | ₹720 Cr | ₹620 Cr | ₹708 Cr | ₹682 Cr | ₹642 Cr |
| Expenses | ₹628 Cr | ₹661 Cr | ₹594 Cr | ₹576 Cr | ₹520 Cr | ₹582 Cr | ₹551 Cr | ₹495 Cr |
| Operating Income | ₹213 Cr | ₹195 Cr | ₹161 Cr | ₹144 Cr | ₹100 Cr | ₹127 Cr | ₹131 Cr | ₹147 Cr |
| Other Income | ₹25 Cr | ₹35 Cr | ₹20 Cr | ₹22 Cr | ₹6 Cr | ₹15 Cr | ₹36 Cr | ₹0 Cr |
| Interest | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Depreciation | ₹25 Cr | ₹24 Cr | ₹24 Cr | ₹27 Cr | ₹23 Cr | ₹23 Cr | ₹21 Cr | ₹20 Cr |
| Profit Before Tax | ₹207 Cr | ₹200 Cr | ₹151 Cr | ₹133 Cr | ₹77 Cr | ₹116 Cr | ₹143 Cr | ₹125 Cr |
| Profit After Tax | ₹159 Cr | ₹149 Cr | ₹114 Cr | ₹99 Cr | ₹58 Cr | ₹91 Cr | ₹105 Cr | ₹98 Cr |
| EPS | ₹3.47 | ₹3.27 | ₹2.50 | ₹2.17 | ₹1.29 | ₹2.00 | ₹2.31 | ₹2.13 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MARKSANS PHARMA | 2% | 23.8% | 90.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -1.4% | 21.7% |
| DIVIS LABORATORIES | 2% | 10.3% | 49.5% |
| TORRENT PHARMACEUTICALS | -0.4% | -0.5% | 38.6% |
| CIPLA | -0.5% | -2.5% | -10.2% |
| DR REDDYS LABORATORIES | -1.2% | 0% | -7.1% |
| MANKIND PHARMA | -1.5% | -3.3% | -4.6% |
| LUPIN | -0.6% | -9.4% | 13% |
| ZYDUS LIFESCIENCES | -3.2% | 2.9% | 19.2% |
MARKSANS PHARMA Quarterly Revenues
| Revenues | |
|---|---|
| Q-o-Q | -1.79 % |
| Y-o-Y | 35.61 % |
| Quarters | Revenues | % Change | |
|---|---|---|---|
| Jun2026 | ₹841 Cr | -1.79 | |
| Mar2026 | ₹856 Cr | 13.48 | |
| Dec2025 | ₹754 Cr | 4.72 | |
| Sep2025 | ₹720 Cr | 16.20 | |
| Jun2025 | ₹620 Cr | -12.49 | |
| Mar2025 | ₹708 Cr | 3.90 | |
| Dec2024 | ₹682 Cr | 6.22 | |
| Sep2024 | ₹642 Cr | - | |
MARKSANS PHARMA Quarterly Operating Profit
| Operating Profit | |
|---|---|
| Q-o-Q | 9.01 % |
| Y-o-Y | 112.77 % |
| Quarters | Operating Profit | % Change | |
|---|---|---|---|
| Jun2026 | ₹213 Cr | 9.01 | |
| Mar2026 | ₹195 Cr | 21.57 | |
| Dec2025 | ₹161 Cr | 11.25 | |
| Sep2025 | ₹144 Cr | 44.32 | |
| Jun2025 | ₹100 Cr | -21.12 | |
| Mar2025 | ₹127 Cr | -2.73 | |
| Dec2024 | ₹131 Cr | -11.11 | |
| Sep2024 | ₹147 Cr | - | |
| Operating Margins | |
|---|---|
| Q-o-Q | 10.99 % |
| Y-o-Y | 56.90 % |
| Quarters | Operating Margin% | % Change | |
|---|---|---|---|
| Jun2026 | 25.34% | 10.99 | |
| Mar2026 | 22.83% | 7.13 | |
| Dec2025 | 21.31% | 6.23 | |
| Sep2025 | 20.06% | 24.21 | |
| Jun2025 | 16.15% | -9.88 | |
| Mar2025 | 17.92% | -6.37 | |
| Dec2024 | 19.14% | -16.31 | |
| Sep2024 | 22.87% | - | |
MARKSANS PHARMA Quarterly Profit After Tax
| Profit After Tax(PAT) | |
|---|---|
| Q-o-Q | 6.96 % |
| Y-o-Y | 173.89 % |
| Quarters | Profit After Tax | % Change | |
|---|---|---|---|
| Jun2026 | ₹159 Cr | 6.96 | |
| Mar2026 | ₹149 Cr | 31.09 | |
| Dec2025 | ₹114 Cr | 14.68 | |
| Sep2025 | ₹99 Cr | 70.34 | |
| Jun2025 | ₹58 Cr | -35.85 | |
| Mar2025 | ₹91 Cr | -13.65 | |
| Dec2024 | ₹105 Cr | 7.47 | |
| Sep2024 | ₹98 Cr | - | |
| PAT Margins | |
|---|---|
| Q-o-Q | 8.90 % |
| Y-o-Y | 101.92 % |
| Quarters | PAT Margin(%) | % Change | |
|---|---|---|---|
| Jun2026 | 18.96 % | 8.90 | |
| Mar2026 | 17.41 % | 15.53 | |
| Dec2025 | 15.07 % | 9.52 | |
| Sep2025 | 13.76 % | 46.54 | |
| Jun2025 | 9.39 % | -26.70 | |
| Mar2025 | 12.81 % | -16.87 | |
| Dec2024 | 15.41 % | 1.18 | |
| Sep2024 | 15.23 % | - | |
MARKSANS PHARMA Quarterly Earnings Per Share (EPS)
| EPS | |
|---|---|
| Q-o-Q | 6.12 % |
| Y-o-Y | 168.99 % |
| Quarters | EPS | % Change | |
|---|---|---|---|
| Jun2026 | ₹3.47 | 6.12 | |
| Mar2026 | ₹3.27 | 30.80 | |
| Dec2025 | ₹2.5 | 15.21 | |
| Sep2025 | ₹2.17 | 68.22 | |
| Jun2025 | ₹1.29 | -35.50 | |
| Mar2025 | ₹2 | -13.42 | |
| Dec2024 | ₹2.31 | 8.45 | |
| Sep2024 | ₹2.13 | - | |
You may also like the below Video Courses